Search form

Search form

Hologic has finalized the acquisition of Sentinelle Medical, a Toronto-based provider of MRI and diagnostic software, for $85 million. The deal, which includes a contingent earn-out for two years, will bolster Hologic's product line of breast cancer detection and intervention technologies.

Related Summaries

The FDA lost about $85 million in medical-device and drug user fees as a result of sequestration, according to an Office of Management and Budget report. "This reaffirms the need to pass legislation that exempts from sequestration the private money FDA collects in user fees so that they may be used by the agency in full for their intended use," Rep. Anna Eshoo, D-Calif., said in response to the report.

An analysis of more than 1,400 breast cancer patients who received Hologic's MammoSite therapy over seven years found that the treatment, which administers targeted radiation to regions thought to be at high risk for cancer growth recurrence, was associated with low local recurrence rates, better than 90% long-term cosmesis and less than 10% toxicity. The findings suggest that MammoSite compares favorably with other types of expedited partial breast irradiation, according to Hologic.

Hologic, a supplier of diagnostic systems for women, has agreed to pay $85 million to acquire Sentinelle Medical, a Toronto-based company that provides MRI breast coils and visualization software. The deal, which is expected to conclude during the third quarter, "should further strengthen our comprehensive portfolio of product offerings in the areas of breast cancer detection and intervention," said Rob Cascella, Hologic's president and CEO.

Hologic has secured European CE Mark approval for its Celero vacuum-assisted core biopsy device. The product is designed to reach lesions in the axilla, as well as other parts of the breast, during ultrasound imaging. Hologic also obtained clearance in Europe for other products, including the CeleroMark and CeleroMark-2S biopsy site identifiers.

Hologic has secured European CE Mark approval for its Celero vacuum-assisted core biopsy device. The product is designed to reach lesions in the axilla, as well as other parts of the breast, during ultrasound imaging. Hologic also obtained clearance in Europe for other products, including the CeleroMark and CeleroMark-2S biopsy site identifiers.